News

Article

CHMP Issues Positive Opinion for Self-Administration of Fasenra

AstraZeneca has revealed that the CHMP of the European Medicines Agency has given a positive opinion to adding a self-administration option for Fasenra (benralizumab).

AstraZeneca has revealed in a July 1, 2019 press statement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given a positive opinion to adding a self-administration option for Fasenra (benralizumab).

Additionally, the CHMP issued a positive opinion for a new delivery method of Fasenra as a pre-filled single-use auto-injector (the Fasenra pen). Both positive opinions will be added to the medicine’s product information in the European Union.

“Fasenra is the only respiratory biologic medicine that can be administered every eight weeks after the initial loading-dose period, and this positive opinion means we are closer to offering Fasenra in a way that is even more convenient for many patients,” said Mene Pangalos, executive vice-president, BioPharmaceuticals R&D, in the press release. “We hope self-administration and the Fasenra pen will play important roles in helping physicians make treatment with biologic medicines accessible to more people with severe eosinophilic asthma.

The CHMP’s positive opinion for Fasenra’s self-administration was supported by Phase III data from the DREGALE and GRECO trials and for the Fasenra pen through Phase I data from the AMES trial. Safety and tolerability of the therapy was found to be consistent with its known profile within the trials.

AstraZeneca has stated that it now anticipates a regulatory decision by the US Food and Drug Administration on the additional option and new delivery method of Fasenra in the second half of 2019.

Source: AstraZeneca

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content